Implementing And Enhancing Evidence-based Research And Practice In Hepatology
Funder
National Health and Medical Research Council
Funding Amount
$569,219.00
Summary
The overall aim of this proposal is to tackle unmet challenges in liver disease research. This will be achieved through (a) Population level programs to deliver new treatments for patients with hepatitis C; (b) Developing integrated care models to treat hepatitis B; (c) Developing population-level programs for liver cancer control; and (d) Identification of patients at risk of severe liver disease through understanding the genetic basis of disease progression.
Improved Health Outcomes For People Living With HIV
Funder
National Health and Medical Research Council
Funding Amount
$560,284.00
Summary
Despite the success of antiviral therapy for HIV infection, HIV cannot be cured and treatment is life long. In addition, there are complications in patients on long term antiviral therapy due to impaired immune recovery. This grant will identify strategies to eliminate HIV from latently infected cells that persist in patients on antiviral therapy as well as identify novel ways to improve the immune response to antiviral treatment for patients with HIV infection as well as patients co-infected wi ....Despite the success of antiviral therapy for HIV infection, HIV cannot be cured and treatment is life long. In addition, there are complications in patients on long term antiviral therapy due to impaired immune recovery. This grant will identify strategies to eliminate HIV from latently infected cells that persist in patients on antiviral therapy as well as identify novel ways to improve the immune response to antiviral treatment for patients with HIV infection as well as patients co-infected with hepatitis B virus (HBV)Read moreRead less
The Future Of HIV Care - Long Term Remission And Eliminating Co-morbidities
Funder
National Health and Medical Research Council
Funding Amount
$577,189.00
Summary
Despite the great successes in antiretroviral therapy (ART) in reducing HIV-associated mortality, treatment is life long and there is no cure. The major barrier to a cure for HIV is the persistence of long lived latently infected cells on ART. Over the next five years I will discover, develop, optimise and evaluate novel interventions to eliminate latently infected cells, long lived infected cells in the liver and enhance HIV-specific immunity through immunotherapy.
Development Of Systemic Therapies To Improve Response And Prevent Resistance In The Treatment Of Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$569,219.00
Summary
This program of research utilises the unique resources at Melanoma Institute Australia (MIA) to understand the biology of prolonged response and resistance to novel drug therapies used in metastatic melanoma, a cancer that now leads the field in the discovery of new targets for therapeutic manipulation. This program also aims to create new methods to efficiently test and develop drug therapy combinations in humans to improve patient outcomes further or prevent metastatic melanoma altogether.
I am an orthopaedic surgeon and clinician-scientist based at Sydney’s largest children’s hospital. My goal is to improve treatments for children with traumatic injuries and bone deformity. I have worked in bone research for over 20 years. My current research interests are finding new treatments for drug-resistant bacterial infections, treating genetic bone disease, and developing new medical devices to help children’s bones grow straight.
Neurobiology Of Childhood Speech And Language Disorders: Advancing Diagnosis, Prognosis And Management
Funder
National Health and Medical Research Council
Funding Amount
$467,961.00
Summary
Half a million Australian children have a speech/language disorder, tripling their changes of poor academic outcomes, limited employment options and social isolation. Current speech therapy is outdated, focusing on symptoms and ignoring important evidence on underlying aetiologies. I will transform detection, diagnosis and treatment of speech/language disorders to optimise patient outcomes, by identifying and translating findings on genes and brain pathways leading to these conditions.
Major advances in cancer treatment has been made by identifying gene mutations in cancers to which the cancer is “addicted”, such that turning off the effects of the mutations leads to death of the cancer cells. Grant McArthur has been successful in applying this principle to rare types of sarcoma bringing his work to routine clinical practice globally. In this application he will investigate targeting the BRAF, KIT and MYC genes focusing on melanoma, a major cancer problem in Australia.
Immunopathogenesis And Manipulation Of The HIV Reservoir
Funder
National Health and Medical Research Council
Funding Amount
$494,732.00
Summary
Kelleher is a Clinical immunologist with a globally recognised, sustained track record of translational research which has impacted both on our understanding of HIV immunopathogenesis and on the way HIV infection is treated. He will conduct a series of studies that encompass basic scientific techniques through to pivotal pre-clinical and clinical studies that will provide a pathway towards control of HIV-infection without daily therapy.
Hepatitis C Vaccines: Preclinical To Clinical Development
Funder
National Health and Medical Research Council
Funding Amount
$474,244.00
Summary
Hepatitis C is one of the most common notifiable infectious diseases in Australia with 200,000 infected individuals and 10,000 new infections each year. Treatments currently available for hepatitis C are effective but also associated with significant side effects and expensive. The economic and health burden of hepatitis C infection and the high costs of emerging antiviral therapies makes the development of an effective vaccine for HCV imperative. This project aims to develop a vaccine for the p ....Hepatitis C is one of the most common notifiable infectious diseases in Australia with 200,000 infected individuals and 10,000 new infections each year. Treatments currently available for hepatitis C are effective but also associated with significant side effects and expensive. The economic and health burden of hepatitis C infection and the high costs of emerging antiviral therapies makes the development of an effective vaccine for HCV imperative. This project aims to develop a vaccine for the prevention of hepatitis C infection.Read moreRead less
Professor Stick is a career clinician researcher in Paediatric Respiratory Medicine. He has established worl-leading research teams focused on respiratory diseases in young children such as cystic fibrosis and asthma. He has has developed innovative methods to study early childhood respiratory diseases and has been responsible for training scores of clinicians and scientists in the field. He has received national and international awards in recognition of his achievements.